Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I, Open-label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1A (Allogenic Engineered T-cells Expressing Anti-CS1 Chimeric Antigen Receptor) Administered in Patients With Relapsed/Refractory Multiple Myeloma

NCT04142619 is registered in ClinicalTrials.gov with Cellectis S.A. as lead sponsor.

NCT NCT04142619
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04142619 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I, Open-label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCARTCS1A (Allogenic Engineered T-cells Expressing Anti-CS1 Chimeric Antigen Receptor) Administered in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Cellectis S.A.
Phase
Phase 1
Overall status
Terminated
Start date
November 21, 2019
Completion date
June 18, 2023
Enrollment
11 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma